An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin 2020, 4 (6), s73. https://doi.org/10.25251/skin.4.supp.73.